Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered quarter ended June 30, 2026.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release includes financial results and corporate updates; investors should review Exhibit 99.1 for details
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $19.6M, or $0.11 per share, versus $9.9M loss prior year
- R&D expense $13.4M, up from $5.3M, reflecting accelerated Phase 3 IMPROVE-PAH development
- IMPROVE-PAH approvals in 26 countries, with 43 clinical sites initiated and approximately 486 planned patients
- June 30 cash, equivalents and marketable securities $159.0M, supplemented by July ATM proceeds of $50M
- Orphan Drug Designation adds potential tax credits, fee exemptions and seven years’ market exclusivity upon approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.